PDLIM2 and esophageal squamous cell carcinoma: However, higher expression of PDLIM2 has also been observed in certain cancer types, such as triple-negative breast cancer, esophageal squamous cell carcinoma, acute myeloid leukemia, and prostate cancer, where it has been suggested as a prognostic marker [67–70].